Dr. Martina RossiPhDSemax research sits within a long-running effort to understand short regulatory peptides derived from adrenocorticotropic hormone (ACTH). The molecule at its center is a small synthetic peptide built from the neuroactive core of ACTH, studied mainly for how it influences neurotrophic factor signaling and for its behavior in models of brain injury. This article summarizes what published preclinical studies show about Semax, focusing on brain-derived neurotrophic factor (BDNF) and related neurotrophic signaling, findings from cerebral ischemia models, and the peptide's reported effect on enkephalin-degrading enzymes, set against the clinical registration context in Russia. Each finding below is identified as coming from a cell culture (in vitro) or an animal model, and nothing here should be read as an outcome an individual should expect. Semax is a research compound and is not characterized here for human use.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is built on the ACTH(4-7) core, Met-Glu-His-Phe, extended at the C-terminus by three additional residues, Pro-Gly-Pro, an addition intended to slow enzymatic breakdown and give the molecule a longer duration than the rapidly degraded parent fragment. The peptide derives from the N-terminal (4-10) region of ACTH. That region carries the neurotropic and behavioral activity historically associated with ACTH, but Semax lacks the corticotropic hormonal action of the full hormone, so it is studied as a neuroactive peptide rather than an endocrine one. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and across the research literature it is typically applied intranasally.
The most developed strand of Semax research concerns neurotrophic factors, the proteins that support neuronal survival, growth, and plasticity. The earliest cellular evidence is in vitro: Shadrina and colleagues reported in 2001 that Semax rapidly induced the messenger RNAs for both nerve growth factor (NGF) and BDNF in rat glial cell cultures, suggesting that its effects on neuronal survival might be mediated through the regulation of neurotrophin expression.[1] Work in living animals then examined the peptide directly in the brain. Dolotov and colleagues reported in 2006 that Semax bound specifically within the rat basal forebrain and increased the level of BDNF protein there,[2] and in a companion study the same group found that a single application in rats increased BDNF protein together with phosphorylation of trkB, the receptor through which BDNF signals, in the hippocampus.[3] A further in vivo study by Agapova and colleagues in 2007 measured neurotrophin gene expression across brain regions and found that Semax produced rapid, gene- and region-specific changes: expression of both NGF and BDNF rose in the hippocampus, BDNF also rose in the brainstem and cerebellum, while NGF expression fell in the frontal cortex.[4] Taken together, these are in vitro and animal findings that point to modulation of neurotrophic signaling rather than a single uniform increase.
A second strand has examined Semax in animal models of cerebral ischemia, where restricted blood flow drives neuronal injury and neurotrophic and vascular signaling become central. Dmitrieva and colleagues reported in 2008 that, in rats subjected to experimental cerebral ischemia, Semax and its C-terminal fragment Pro-Gly-Pro altered the expression of several growth factor genes and their receptors in the affected brain tissue.[5] Extending this to the vascular side of the response, Medvedeva and colleagues reported in 2013 that, in a rat model of focal cerebral ischemia, Semax and Pro-Gly-Pro influenced the expression of vascular endothelial growth factor (VEGF) family genes and their receptors.[6] Both are animal findings that characterize how the peptide interacts with the molecular response to ischemic injury, and neither predicts an outcome in an organism beyond the model.
A distinct line of work concerns the endogenous opioid system. Kost and colleagues reported in 2001 that Semax, along with the related peptide Selank, dose-dependently inhibited enkephalin-degrading enzymes from human serum in vitro.[7] By slowing the enzymatic breakdown of enkephalins, the peptide is thought to prolong endogenous enkephalin signaling rather than acting directly on opioid receptors. Animal behavior is broadly consistent with an opioid-related action: Manchenko and colleagues reported in 2010 that Semax produced an analgesic effect in rats in the Randall-Selitto paw-withdrawal test following intraperitoneal administration, with the analgesic and nootropic effects showing different route dependence.[8] It is worth being precise about the evidence here. The enzyme inhibition is an in vitro biochemical finding, the analgesia is an animal behavioral finding, and the link between them, that inhibited enkephalin breakdown produces the observed analgesia, remains a proposed mechanism rather than a directly measured chain.
The directly relevant mechanistic and neurotrophic evidence on Semax is preclinical, drawn from cell and animal studies. Semax is also registered as a medicinal product in Russia and has been investigated in clinical settings there, including early work by Miasoedova and colleagues on the mechanisms of its reported neuroprotective effect in the acute period of ischemic stroke.[9] That clinical and regulatory context is specific to Russia and is distinct from the research-grade compound discussed here, and no personal outcome should be inferred from it.
Several limitations shape how this literature should be read. A large share of the work originates from a small network of affiliated Russian institutes, and much of it is published in Russian-language journals, which limits independent replication. The proposed mechanisms are multiple, spanning neurotrophic, enkephalinergic, and vascular signaling, and the neurotrophic effects themselves are region-specific rather than uniform, so a single unifying account is not yet settled. Human pharmacokinetic and long-term safety data available in the international literature are limited.
Semax is best understood as a metabolically stabilized, ACTH(4-10)-derived heptapeptide studied as a neuroactive peptide without the hormonal action of the parent molecule. Its preclinical profile points to a multi-target picture: modulation of NGF and BDNF signaling in cell and animal studies, altered growth factor and VEGF gene expression in animal ischemia models, and inhibition of enkephalin-degrading enzymes in vitro alongside analgesic activity in animals. Semax is intended for laboratory research use only, and the findings above describe what has been investigated, not what any individual should expect.
Semax is available for laboratory research from Pure Peptides. View Product →
References
WRITTEN BY
Dr. Martina Rossi
PhD — Scientific Contributor and Reviewer
Dr. Martina Rossi holds a PhD from Universite Grenoble Alpes, where her doctoral research examined the vascular functions of Bone Morphogenetic Proteins in knockout mouse models. Her published work spans cell and molecular biology, vascular biology, and gene therapy, with peer-reviewed contributions appearing in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. Dr. Rossi serves as Scientific Contributor and Reviewer for the Pure Peptides research content program, independently reviewing articles for scientific accuracy.
View team profile →
Preclinical Selank research on GABAergic signaling, enkephalin mechanisms and anxiolytic peptide biology, with evidence clearly tiered. Research use only.
